Have you got any ? http://www.africanseer.com/elysium-health-basis-uk-190a.pdf elysium health basis supplement  "While Street expectations were low for ramucirumab in breast, they were not quite this low," ISI Group analyst Mark Schoenebaum wrote in a note, saying the drug was expected to delay worsening of breast cancer but not extend survival.